Nectar Lifesciences Share Price | Nectar Lifesciences Stock Screener
NECLIFE
Pharmaceuticals
Share Price NSE
₹14.36
▲
0.80 (5.90%)
Share Price BSE
₹11.51
▼
-0.17 (-1.46%)
As of May 8, 2026, the Nectar Lifesciences share price (NSE: NECLIFE) is ₹14.36 on NSE and ₹11.51 on BSE, up 5.90% from the previous close, with shares trading between ₹13.77 and ₹14.91, and a 52-week range of ₹9.30–₹20.95.
Check NECLIFE 52-week performance for the annual price range and momentum.
Use the Nectar Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Nectar Lifesciences Market Cap
₹229.62 Cr.
NECLIFE P/E Ratio (TTM)
-0.76
Nectar Lifesciences P/B Ratio
0.38
EPS (TTM)
₹-13.40
Dividend Yield
-
Debt to Equity
0.60
NECLIFE 52 Week High
₹20.95
Nectar Lifesciences 52 Week Low
₹9.30
Operating Margin
-
Profit Margin
-1133.33%
NECLIFE Revenue (TTM)
₹6.00
EBITDA
₹-83.00
Net Income
₹-68.00
Total Assets
₹622.00
Total Equity
₹582.00
Nectar Lifesciences Share Price Chart
Screen Nectar Lifesciences share price with an interactive chart. Analyse NECLIFE price trends and volatility across different timeframes.
Nectar Lifesciences Company Profile - Fundamental Screener
Screen Nectar Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NECLIFE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE023H01027
Nectar Lifesciences Balance Sheet Screener
Screen NECLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 622 | 2,047 | 2,191 | 2,189 | 2,391 | 2,471 | 2,633 | 2,705 | 2,724 | 2,581 |
| Current Assets | 289 | 1,238 | 1,284 | 1,231 | 1,355 | 1,239 | 1,615 | 1,669 | 1,661 | 1,496 |
| Fixed Assets | 103 | 633 | 643 | 662 | 723 | 772 | 785 | 825 | 852 | 881 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 9 | 70 | 149 | 234 | 299 | 222 | 249 | 300 | 356 | 296 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 582 | 956 | 1,069 | 1,065 | 1,088 | 1,062 | 1,136 | 1,105 | 1,059 | 1,007 |
| Share Capital | 19 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves & Surplus | 563 | 934 | 1,047 | 1,042 | 1,066 | 1,040 | 1,114 | 1,083 | 1,036 | 984 |
Nectar Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Nectar Lifesciences income statement and profit fundamentals.
Analyze NECLIFE quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Nectar Lifesciences share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 0 | 6 | 0 | 36 | 441 | 359 | 12 | 8 | 406 | 395 | 409 | 453 | 477 | 403 |
| Expenses | 89 | 130 | 69 | 177 | 2 | 393 | 320 | 6 | 0 | 371 | 359 | 371 | 410 | 427 | 361 |
| EBITDA | -83 | -130 | -63 | -176 | 34 | 49 | 40 | 6 | 8 | 35 | 36 | 38 | 43 | 50 | 42 |
| Operating Profit % | 0.00% | 0.00% | -1212.00% | 0.00% | 0.00% | 11.00% | 11.00% | -10.00% | 0.00% | 4.00% | 9.00% | 7.00% | 9.00% | 10.00% | 10.00% |
| Depreciation | 0 | 0 | 1 | 0 | 0 | 15 | 16 | 0 | 0 | 15 | 15 | 15 | 15 | 14 | 15 |
| Interest | 6 | 0 | 0 | 0 | 30 | 24 | 20 | 0 | 0 | 20 | 18 | 21 | 25 | 17 | 21 |
| Profit Before Tax | -88 | -130 | -64 | -176 | 3 | 11 | 5 | 6 | 8 | 2 | 3 | 2 | 3 | 18 | 6 |
| Tax | -20 | 0 | 0 | 0 | -11 | 11 | 2 | 0 | 0 | -2 | 1 | 1 | 1 | 6 | 2 |
| Net Profit | -68 | -130 | -63 | -176 | 14 | 1 | 3 | 6 | 8 | 4 | 2 | 1 | 2 | 12 | 4 |
| EPS | -3.38 | -5.80 | -2.82 | -7.85 | 0.64 | 0.03 | 0.13 | 0.25 | 0.35 | 0.16 | 0.08 | 0.05 | 0.07 | 0.52 | 0.17 |
Nectar Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen NECLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 169 | 225 | 134 | 95 | 21 | 285 | 239 | 65 | 199 | 169 |
| Investing Activities | -42 | -17 | 52 | 17 | -29 | -33 | -26 | -29 | -18 | -77 |
| Financing Activities | -128 | -205 | -186 | -119 | 12 | -252 | -201 | -40 | -204 | -89 |
| Net Cash Flow | -1 | 2 | 0 | -8 | 4 | 0 | 12 | -4 | -24 | 3 |
Nectar Lifesciences Shareholding Pattern Screener
See Nectar Lifesciences shareholding pattern with promoter, FII, and DII holdings.
Check Nectar Lifesciences promoter holding and ownership changes for NECLIFE on TickJournal.
| Item | 2026-Jan | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.84% | 51.84% | 44.53% | 44.53% | 44.91% | 44.91% | 55.80% | 55.80% |
| FII Holding | 0.58% | 0.60% | 1.65% | 0.81% | 0.62% | 0.52% | 16.97% | 16.61% |
| DII Holding | 3.54% | 4.01% | 0.16% | 0.19% | 0.09% | 5.82% | 0.00% | 0.00% |
| Govt Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public Holding | 35.83% | 36.23% | 41.60% | 44.12% | 44.70% | 39.72% | 23.32% | 23.69% |
| Other Holding | 8.18% | 7.29% | 12.04% | 10.32% | 9.67% | 9.00% | 3.88% | 3.87% |
| Shareholder Count | 76,648 | 74,834 | 69,241 | 71,977 | 76,470 | 78,124 | 59,946 | 58,230 |
Nectar Lifesciences Share Dividend Screener - Share Yield Analysis
Check Nectar Lifesciences dividend history with payout and yield data.
View Nectar Lifesciences dividend details including ex-dates and amounts for NECLIFE stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.05 | 0.27% |
| 2019-March | ₹0.05 | 0.51% |
| 2018-March | ₹0.05 | 0.29% |
| 2017-March | ₹0.05 | 0.19% |
Nectar Lifesciences Stock Index Membership
See which indices include Nectar Lifesciences stock.
Check NECLIFE index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Nectar Lifesciences Market Events Screener - Corporate Actions
Get Nectar Lifesciences corporate actions including splits, bonuses, and buybacks.
Check Nectar Lifesciences stock events that may affect NECLIFE share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -5.38% | ||
| Annual General Meeting | NA | 41.10% | ||
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 3.23% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -4.39% |
| 2025-12-24 | 2026-12-31 | Buyback | 27 | -2.67% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 8.67% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 8.63% |
| 2025-08-04 | 2025-08-04 | Extraordinary General Meeting | NA | -28.60% |
| 2025-07-07 | 2025-07-07 | Quarterly Result Announcement | NA | -9.14% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | -18.01% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -11.31% |
Nectar Lifesciences Competitors Screener - Peer Comparison
Screen NECLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 446,972 | 38.30 | 58,220 | 6.38% | 11,565 | 64.62 |
| Divis Laboratories | 180,187 | 69.69 | 10,560 | 8.73% | 2,520 | 57.29 |
| Torrent Pharmaceuticals | 150,845 | 70.06 | 13,886 | 20.34% | 2,138 | 52.62 |
| Cipla | 114,358 | 28.32 | 29,045 | 2.24% | 3,870 | 60.96 |
| Zydus Life Science | 109,227 | 21.03 | 26,720 | 13.65% | 5,242 | 59.83 |
| Dr Reddys Laboratories | 107,727 | 25.53 | 33,593 | -0.44% | 3,998 | 53.01 |
| Lupin | 106,948 | 20.08 | 27,488 | 19.98% | 5,345 | 59.95 |
| Mankind Pharma | 104,782 | 51.51 | 14,278 | 12.03% | 1,750 | 68.38 |
| Aurobindo Pharma | 86,650 | 24.84 | 33,385 | 3.21% | 3,376 | 58.58 |
| Laurus Labs | 77,518 | 85.73 | 6,868 | 22.01% | 890 | 67.21 |
Nectar Lifesciences Company Announcements - News Screener
Screen NECLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-06-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Financial Results For The Year 2025-26 | - |
| 2026-05-25 | Board Meeting Intimation for Audited Financial Results And Other Business Matters | - |
| 2026-04-28 | Update On Slump Sale | - |
| 2026-04-28 | Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-04-18 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-04-08 | Second 100 Days Saksham Niveshak Campaign- Shareholder Outreach Initiative. | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-25 | Closure of Trading Window | - |
| 2026-03-24 | Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-13 | Minutes Of The Ordinary/ Special Resolutions Passed By Way Of Postal Ballot | - |
| 2026-03-12 | Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-07 | Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-06 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-03-03 | General Updates | - |
| 2026-03-02 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-03-02 | Board Meeting Outcome for Meeting Held On March 02 2026 | - |
| 2026-03-01 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-01-30 | Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011 | - |